57 results about "Isotretinoin" patented technology

Zeaxanthin, a natural carotenoid, can improve and increase the ability of enzyme inhibitors that can slow down certain enzymes that are contributing to toxic metabolite accumulation in people who suffer from Stargardt's disease or other lipofuscin disorders. Such enzyme inhibitors include retinoid analogs such as isotretinoin, commonly known by the trademark, ACCUTANE. This drug binds to and inhibits at least two retinal enzymes, known as RPE65 and short chain dehydrogenase, which create surplus metabolites that feed into a pathway that eventually creates toxic metabolites in people with Stargardt's disease. However, isotretinoin treatment alone is not highly effective; therefore, use of zeaxanthin as an adjunctive treatment can improve the efficacy and outcomes of such treatments.

The present invention provides unique, efficacious, inexpensive, safe, reliable, convenient, minimally bitter, skin protecting and penetrating, easy-to-administer base compositions and active agent-containing compositions, such as those including hydrocortisone, and related production and topical application methods, for treating the skin of mammals for a wide variety of different dermatologic conditions, disorders and diseases, such as inflammation, redness, cracking, insect bites, dryness, allergic reactions, trauma, irritant dermatitis, perleche, contact dermatitis, psoriasis, eczema, seborrheic dermatitis, acne excoriate, xerosis, eczema craquele, stasis dermatitis, disease related conditions and dryness from medications such as isotretinoin, acitretin and lipid lowering agents. This is effected by topically administering, or otherwise applying, effective amounts of the compositions thereto in forms that not only address the skin and mucosa of the mouth and lips, but also of the rest of the body and, in particular, areas where other topical balms containing hydrocortisone and other active ingredients have not been developed or marketed. Additionally, the flavoring addition to this product, and the base wherein the active ingredient(s) reside, affords a significantly better tasting, and less bitter, composition, thereby allowing a more pleasant experience and better compliance by patients. Larger sized stick formulation(s) allow for more applicability of the product, and more usefulness thereof, in various areas, and mucosal skin, of the body. The compositions include a unique formulation of FANCOL VB, Natunola Castor 1023, Finsolv TN, bees wax and, optionally, one or a plurality of plant or plant seed oils, fatty alcohols, fats and flavorings, in desirable weight percents thereof, in various forms, and preferably in the form of a solid roll-on stick present in a variety of sizes.

An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle

The present invention relates to a pharmaceutical solution comprising isotretinoin or salts thereof. The present invention further relates to the processes for preparing such compositions.

The invention relates to an oral pharmaceutical composition of isotretinoin at least two excipients, one of the excipients being a hydrophilic excipient having an HLB value greater than or equal to 10 and the other excipient being an oily vehicle. The oral pharmaceutical composition is substantially devoid of food effect as characterized by a dissolution profile wherein at least 70% of the oral pharmaceutical composition is dissolved after about four hours in a USP2 dissolution apparatus at a paddle speed of 100 rpm, and a dissolution media composed of 900 mL of pH 7.5 buffer containing 0.11% pancreatin, 4.7% cholic acid, 0.14% sodium dihydroxide phosphate and 0.5% sodium hydroxide at 37° C.

The acne treating medicine composition consists of Ethinylestradiol, compound sulfamethoxazole, promethazine, chlorpheniramine, dexamethasone, isotretinoin, chloromycetin, vitamin E and vanishing cream. The present invention can heal acne radically according to the pathogenesis, has unique acne healing effect, and has the functions of eliminating scar, nourishing skin, beautifying, etc. when used regularly. The present invention has fast effect and no toxic side effect.

The present invention provides pharmaceutical compositions for the treatment of acne comprising co-administering a therapeutically effective amount of isotretinoin and a contraceptive in a contraceptively effective dosage wherein the contraceptive does not contain 100 wt % progesterone. Methods of treating acne and unit dosage delivery systems are also provided.

The invention relates to the field of medicinal chemistry, in particular to a crystal form preparation process and application of isotretinoin. A crystal form A takes positions 2theta of diffraction peaks as spectrogram feature parameters, wherein the positions 2theta sequentially comprise 5.8+/-0.2, 10.52+/-0.2, 11.46+/-0.2, 11.87+/-0.2, 12.56+/-0.2, 15.83+/-0.2, 16.49+/-0.2, 18.11+/-0.2, 19.70+/-0.2, 20.24+/-0.2, 21.68+/-0.2, 24.83+/-0.2, 25.40+/-0.2, 26.94+/-0.2, 28.62+/-0.2, and 30.87+/-0.2. A specific preparation method comprises the steps that an isotretinoin raw material is dissolved with organic alcohol to obtain an isotretinoin organic alcohol solution, crystallization is conducted with a temperature differential method, solid-liquid separation is conducted, a solid is dried and then the crystal form A is obtained; the crystal form A is put under light in air and the stability of the crystal form A is obviously better than that of a raw material medicine.

This invention provides one different dimensional A acid capsule solvent degree and its anti-oxidant and antiseptic identification method, which improves the capsule quality standard helpful for monitor product initial period and effective storage period with large application value.

The invention discloses a method for preparing 13-cis isotretinoin. The method comprises the following steps: directly adding an acid to a solution containing a compound represented by formula I and a compound represented by formula IV and generated through a WITTIG reaction to adjust the pH value to 5-10, adding a palladium compound or a rhodium compound, and carrying out an isomerization reaction to obtain a product with the configuration represented by formula I. The 13-cis isotretinoin preparation is completed in a one step mode through a series of reactions comprising the WITTIG reaction and the isomerization reaction without hydrolysis, extraction or distillation after the WITTIG reaction, so the method has the advantages of step simplification, yield increase, total yield reaching 90%, low cost, and suitableness for industrial production.

Dermatological compositions contain, formulated into a physiologically acceptable medium, at least one retinoid compound selected from among all-trans retinoic acid, isotretinoin, motretinide, and naphthoic acid compounds of formula (I), and salts and esters thereof:

wherein R is a hydrogen atom, a hydroxyl radical, a branched or unbranched alkyl radical having from 1 to 4 carbon atoms, an alkoxy radical having from 1 to 10 carbon atoms or a cycloaliphatic radical which is substituted or unsubstituted, and at least one anti-irritant compound and benzoyl peroxide.

The invention discloses an isotretinoin amido alkyl benzoate derivative, a preparation method thereof and applications thereof. The derivative has stronger inhibition and differentiation regulating effects than isotretinoin on psoriasis, acne and epithelial cell tumors including, but not limited to skin squamous epithelial cell carcinoma, stomach cancer, lung cancer, and cervical cancer; the derivative has less influence on normal tissue cells, has a certain targeting effect on inhibiting proliferating cells, and has very less side effects than isotretinoin; and the derivative has wide promising prophylaxis and treatment applications such as cornification abnormality diseases and cell abnormal proliferation including tumors, psoriasis, acne, and other cornification abnormality dermatopathy.

An object of the present invention is to provide a medicine that can simply treat and/or prevent a retinal degenerative disease associated with photoreceptor degeneration, including retinitis pigmentosa. The solution is to provide an agent for treating and/or preventing a retinal degenerative disease associated with photoreceptor degeneration, containing a compound having a retinoic acid receptor agonistic activity (for example, tamibarotene, tamibarotene methyl ester, tamibarotene ethyl ester, tazarotene, tazarotenic acid, adapalene, palovarotene, retinol, isotretinoin, alitretinoin, etretinate, acitretin or bexarotene) or a salt thereof.

Disclosed herein, in part, is a pharmaceutical formulation comprising isotretinoin or a pharmaceutically acceptable salt thereof, and a mucoadhesive polymer. A method of treating a mucosal disease comprising administering a disclosed pharmaceutical formulation to a subject in need thereof is also provided herein.

The present invention relates to a topical solution comprising a retinoid or its pharmaceutically acceptable salts thereof and process of preparing it.

This invention relates to a dietary supplement that is specifically designed for use in three categories of patient type; patients undergoing treatment with oral or topical forms of retinoids such as Isotretinoin, Tretinoin and Retinoic Acid; patients with medical conditions/treatments that are aggravated by the consumption of Vitamin A; individuals in the prenatal period wishing to avoid the consumption of Vitamin A in supplements.

The dietary supplement is not limited by the inclusion of specific vitamins, minerals or other nutrients, but rather the exclusion specifically of Vitamin A and/or its precursors for the purpose outlined above.

The present application relates to pharmaceutical compositions comprising retinoic acid or its derivatives such as isotretinoin and processes for preparing thereof. It also provides methods for treating acne by administering such pharmaceutical composition to a patient in need thereof.

The present invention relates to a medicament, the active ingredient combination of which consists of a retinoid selected from the group consisting of acitretin [9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid], etretinate [ethyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate], isotretinoin [3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid] and tretinoin [3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid] and of a hormone combination with contraceptive action of an oestrogen component and a gestagen component, and to a dosage form consisting of at least 28 daily units, of which the final 7-3 daily units contain only the retinoid as active ingredient and the other daily units also contain the hormone-containing active ingredient combination, and to the use thereof for treating acne, seborrhoea or psoriasis.

The invention discloses an ointment for treating verruca plana and a preparation method thereof. The ointment comprises the following substances: horse fat, rose hip, an AC-402 compound emulsifier, a natural GOC emulsifier, isotretinoin, a coix seed extract, a dictamnus bark extract, a white mulberry root bark extract, an isatis root extract, a kochia fruit extract, a stemona root extract, a purslane herb extract, a flavescent sophora root extract, carbomer 941, ethylparaben, carboxymethylcellulose sodium, a 75% ethanol solution, distilled water, and essence. Compared with the prior art, the ointment emulsion can eliminate source of virus, inhibit breeding of bacteria and fungi, enhance immunocompetence of skin, realize effects of cleaning and sterilization, effectively treat viral verruca plana, eliminate verruca with obvious effects, promote absorption of effective components by skin, improve blood circulation in skins, promote metabolism, recover normal barrier function of skin, perfect surface layers, and prevent recurrence of verruca plana.

The invention provides a tyrosinase-inhibiting whitening cream of a natural extract and preparation equipment of the tyrosinase-inhibiting whitening cream. The whitening cream comprises a whitening agent, an emollient, a thickener, a skin conditioner and an emulsifier, and the whitening agent comprises 0.5-7% of lipoic acid, 0.05-0.5% of coenzyme, 0.01-3% of acetyl-L-carminine hydrochloride, 0.01-2% of allantoin and 0.1-10% of isotretinoin; the emollient comprises 9.5% of grease, 6-10% of ethylhexyl palmitate, 3-5% of caprylic/capric triglyceride, 3-7% of isononyl isononanoate, 2-4% of polydimethylsiloxane, 2-4% of 1, 2-pentanediol, 0.45-0.55% of avocado tree fruit fat, 0.18-0.22% of 1, 2-hexanediol and 0.2-0.5% of caprylyl glycol; and the thickener comprises 2-5% of cetostearyl alcohol, 0.36-0.44% of carbomer and 0.2% of xanthan gum. According to the present invention, natural plant whitening components are prepared into natural cosmetics, the natural cosmetics directly act on facialskin, effective components of the natural cosmetics permeate into a skin basal layer, existing melanin is reduced and decomposed, cells are activated, facial spots are faded, compatibility is reasonable, and the skin is whitened, moistened, moisturized, glossy and fine.